Chemistry: molecular biology and microbiology – Spore forming or isolating process
Patent
1993-11-24
1997-09-23
Fitzgerald, David L.
Chemistry: molecular biology and microbiology
Spore forming or isolating process
435 71, 435 721, 435 691, 4353201, 4352523, 43525411, 530350, 536 235, C07K 1472, C12N 1512, C01N 3353
Patent
active
056703600
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a recombinant glucagon-like peptide-1 (GLP-1) receptor, to a DNA construct which comprises a DNA sequence encoding a GLP-1 receptor, to methods of screening for agonists of GLP-1 activity, and to the use of the GLP-1 receptor for screening for agonists of GLP-1 activity.
BACKGROUND OF THE INVENTION
As used in the present specification the designation GLP-1 comprises GLP-1(7-37) as well as GLP-1(7-36)amide.
Glucose-induced insulin secretion is modulated by a number of hormones and neurotransmitters. In particular, two gut hormones, glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) potentiate the effect of glucose on insulin secretion and are thus called gluco-incretins (Dupre, in The Endocrine Pancreas, E. Samois Ed. (Raven Press, New York, (1991), 253-281) and Ebert and Creutzfeld, (Diabetes Metab. Rev. 3, (1987)). Glucagon-like peptide-1 is a glucoincretin both in rat and in man (Dupre and Ebert and Creutzfeld, vide supra, and Kreymann et al. (Lancet 2 (1987), 1300)). It is part of the preproglucagon molecule (Bell et al. Nature 304 (1983), 368) which is proteolytically processed in intestinal L cells to GLP-1(1-37) and GLP-1(7-36)amide or GLP-1(7-37) (Mojsov et al. (J. Biol. Chem. 261 (1986), 11880) and Habener et al.: The Endocrine Pancreas E. Samois Ed. (Raven Press, New York (1991), 53-71). Only the truncated forms of GLP-1 are biologically active and both have identical effects on insulin secretion in beta cells (Mojsov et al. J. Clin. Invest 79 (1987), 616) and Weir et al. (Diabetes38 (1989), 338). They are the most potent gluco-incretins so far described and are active at concentrations as low as one to ten picomolar. The stimulatory effect of these gluco-incretin hormones requires the presence of glucose at or above the normal physiological concentration of about 5 mM and is mediated by activation of adenylate cyclase and a rise in the intracellular concentration of cyclic AMP (Drucker et al. Proc. Natl. Acad. Sci. USA 84 (1987), 3434) and Goke et al. (Am. J. Physiol. 257 (1989), G397). GLP-1 has also a stimulatory effect on insulin gene transcription (Drucker et al. Proc. Natl. Acad. Sci. USA 84 (1987), 3434). Non-insulin-dependent diabetes mellitus (NIDDM) is associated with a reduced stimulatory effect of GLP-1 on glucose-induced insulin secretion (Suzuki et al. Diabetes 39 (1990), 1320). In man, in one study, GLP-1 levels were elevated in NIDDM patients both in the basal state and after glucose ingestion; however, following a glucose load there was only a very small rise in plasma insulin concentration (.O slashed.rskov et al. J. Clin. Invest. 87 (1991), 415). A recent study (Nathan et al. Diabetes Care 15 (1992), 270) showed that GLP-1 infusion could ameliorate postprandial insulin secretion and glucose disposal in NIDDM patients. Thus, as a further step in understanding the complex modulation of insulin secretion by gut hormones and its dysfunction in diabetes, we isolated and characterized a complementary DNA for the beta cell GLP-1 receptor and showed that it is part of a new family of G-coupled receptors.
DESCRIPTION OF THE INVENTION
The present invention relates to a recombinant glucagon-like peptide-1 (GLP-1) receptor.
More preferably, the invention relates to a GLP-1 receptor which comprises the amino acid sequence shown in SEQ ID No. 1, or an analogue thereof binding GLP-1 with an affinity constant, K.sub.D, below 100 nM, preferably below 10 nM. In the present context, the term "analogue" is intended to indicate a naturally occurring variant (including one expressed in other animal species, in particular human) of the receptor or a "derivative" i.e. a polypeptide which is derived from the native GLP-1 receptor by suitably modifying the DNA sequence coding for the variant, resulting in the addition of one or more amino acids at either or both the C- and N-terminal ends of the native amino acid sequence, substitution of one or more amino acids at one or more sites in the native amino acid sequence, deletio
REFERENCES:
Richter et al., FEBS Letters, vol. 267, No. 1, pp. 78-80 (1990).
Uttenthal et al., FEBS Letters, vol. 262, No. 1, pp. 139-141 (1990).
Thorens, Proc. Natl. Acad. Sci., vol. 89, No. 18, pp. 8641-8645 (1992).
Saxena, B. B., et al. (1986) Biochem. 25: 7943-50.
Juppner, H., et al. (1991) Science 254: 1024-26.
Lin, H. Y., et al. (1991) Science 254: 1022-24.
Goke et al. (1992) FEBS Lett. 300(3): 232-36.
Lankat-Buttgerett, B., et al. (1994) Exp. Clin. Endocrinol. 102: 341-347.
Watson, S., et al. (1994) The G-Protein Linked Receptor Facts Book, London: Academic Press, pp. 128-129.
Fitzgerald David L.
Harrington Esq. James J.
Novo Nordisk A S
Zelson Esq. Steve T.
LandOfFree
Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1938338